Immunotherapy in Progressive Supranuclear Palsy

Overview

Journal Curr Opin Neurol

Specialty Neurology

Date 2020 Jul 14

PMID 32657895

Citations 4

Authors

Pavan A Vaswani

Abby L Olsen

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Progressive supranuclear palsy (PSP) is a progressive adult-onset neurodegenerative disease. Abnormally, phosphorylated forms of the microtubule-associated protein tau containing four repeat domains (4R-tau) aggregate in neurons. Additionally, increasing evidence suggests that secretion and uptake of fragments of abnormal 4R-tau may play a role in disease progression. This extracellular tau is a natural target for immunotherapy.

Recent Findings: Three monoclonal antibodies targeting extracellular tau are in clinical stages of development. ABBV-8E12 and BIIB092 were safe in Phase 1, but both Phase two studies recently failed futility analyses. UCB0107 recently reported (in abstract form) Phase 1 safety results, and a Phase 2 study is under consideration. Stem cell therapy and the infusion of plasma are also being explored clinically.

Summary: The likely role of extracellular tau in the progression of PSP makes tau a natural target for targeted immunotherapy. Clinical trials are still in early stages, and although tau immunotherapy has largely been shown to be safe, efficacy has yet to be demonstrated.

Citing Articles

Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.

Dunning E, Decourt B, Zawia N, Shill H, Sabbagh M Neurol Ther. 2024; 13(4):975-1013.

PMID: 38743312 PMC: 11263316. DOI: 10.1007/s40120-024-00614-9.

Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Dam T, Boxer A, Golbe L, Hoglinger G, Morris H, Litvan I Nat Med. 2021; 27(8):1451-1457.

PMID: 34385707 DOI: 10.1038/s41591-021-01455-x.

Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care.

Bluett B, Pantelyat A, Litvan I, Ali F, Apetauerova D, Bega D Front Neurol. 2021; 12:694872.

PMID: 34276544 PMC: 8284317. DOI: 10.3389/fneur.2021.694872.

Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.

Castonguay A, Gravel C, Levesque M J Parkinsons Dis. 2020; 11(1):71-92.

PMID: 33104039 PMC: 7990466. DOI: 10.3233/JPD-202221.

References

Hoglinger G, Respondek G, Stamelou M, Kurz C, Josephs K, Lang A . Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017; 32(6):853-864. PMC: 5516529. DOI: 10.1002/mds.26987. View

Leyns C, Holtzman D . Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener. 2017; 12(1):50. PMC: 5492997. DOI: 10.1186/s13024-017-0192-x. View

Courade J, Angers R, Mairet-Coello G, Pacico N, Tyson K, Lightwood D . Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau. Acta Neuropathol. 2018; 136(5):729-745. PMC: 6208734. DOI: 10.1007/s00401-018-1911-2. View

Williams D, de Silva R, Paviour D, Pittman A, Watt H, Kilford L . Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain. 2005; 128(Pt 6):1247-58. DOI: 10.1093/brain/awh488. View

Whitwell J, Hoglinger G, Antonini A, Bordelon Y, Boxer A, Colosimo C . Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Mov Disord. 2017; 32(7):955-971. PMC: 5511762. DOI: 10.1002/mds.27038. View

Jadhav S, Avila J, Scholl M, Kovacs G, Kovari E, Skrabana R . A walk through tau therapeutic strategies. Acta Neuropathol Commun. 2019; 7(1):22. PMC: 6376692. DOI: 10.1186/s40478-019-0664-z. View

Canesi M, Giordano R, Lazzari L, Isalberti M, Isaias I, Benti R . Finding a new therapeutic approach for no-option Parkinsonisms: mesenchymal stromal cells for progressive supranuclear palsy. J Transl Med. 2016; 14(1):127. PMC: 4862050. DOI: 10.1186/s12967-016-0880-2. View

Mudher A, Colin M, Dujardin S, Medina M, Dewachter I, Naini S . What is the evidence that tau pathology spreads through prion-like propagation?. Acta Neuropathol Commun. 2017; 5(1):99. PMC: 5735872. DOI: 10.1186/s40478-017-0488-7. View

Lykhmus O, Koval L, Voytenko L, Uspenska K, Komisarenko S, Deryabina O . Intravenously Injected Mesenchymal Stem Cells Penetrate the Brain and Treat Inflammation-Induced Brain Damage and Memory Impairment in Mice. Front Pharmacol. 2019; 10:355. PMC: 6479176. DOI: 10.3389/fphar.2019.00355. View

10.

Qureshi I, Tirucherai G, Ahlijanian M, Kolaitis G, Bechtold C, Grundman M . A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement (N Y). 2018; 4:746-755. PMC: 6298197. DOI: 10.1016/j.trci.2018.10.007. View

11.

Richardson J, Steele J, Olszewski J . SUPRANUCLEAR OPHTHALMOPLEGIA, PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. A CLINICAL REPORT ON EIGHT CASES OF "HETEROGENOUS SYSTEM DEGENERATION". Trans Am Neurol Assoc. 1963; 88:25-9. View

12.

Shin J, Park H, Kim H, Oh S, Bae J, Ha H . Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models. Autophagy. 2013; 10(1):32-44. PMC: 4389879. DOI: 10.4161/auto.26508. View

13.

Park H, Shin J, Kim H, Oh S, Lee P . Neuroprotective effects of mesenchymal stem cells through autophagy modulation in a parkinsonian model. Neurobiol Aging. 2014; 35(8):1920-8. DOI: 10.1016/j.neurobiolaging.2014.01.028. View

14.

Reza-Zaldivar E, Hernandez-Sapiens M, Gutierrez-Mercado Y, Sandoval-Avila S, Gomez-Pinedo U, Marquez-Aguirre A . Mesenchymal stem cell-derived exosomes promote neurogenesis and cognitive function recovery in a mouse model of Alzheimer's disease. Neural Regen Res. 2019; 14(9):1626-1634. PMC: 6557105. DOI: 10.4103/1673-5374.255978. View

15.

Turner L . The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions. Perspect Biol Med. 2018; 61(1):7-24. DOI: 10.1353/pbm.2018.0024. View

16.

Holmes B, Furman J, Mahan T, Yamasaki T, Mirbaha H, Eades W . Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014; 111(41):E4376-85. PMC: 4205609. DOI: 10.1073/pnas.1411649111. View

17.

Boxer A, Qureshi I, Ahlijanian M, Grundman M, Golbe L, Litvan I . Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019; 18(6):549-558. DOI: 10.1016/S1474-4422(19)30139-5. View

18.

Kahlson M, Colodner K . Glial Tau Pathology in Tauopathies: Functional Consequences. J Exp Neurosci. 2016; 9(Suppl 2):43-50. PMC: 4750898. DOI: 10.4137/JEN.S25515. View

19.

Mendes-Pinheiro B, Anjo S, Manadas B, Da Silva J, Marote A, Behie L . Bone Marrow Mesenchymal Stem Cells' Secretome Exerts Neuroprotective Effects in a Parkinson's Disease Rat Model. Front Bioeng Biotechnol. 2019; 7:294. PMC: 6838134. DOI: 10.3389/fbioe.2019.00294. View

20.

Steele J, Richardson J, Olszewski J . PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA. Arch Neurol. 1964; 10:333-59. DOI: 10.1001/archneur.1964.00460160003001. View